ChronoScale Corporation Common Stock (NASDAQ:CHRN) Posts Earnings Results

ChronoScale Corporation Common Stock (NASDAQ:CHRN – Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.29) EPS for the quarter, FiscalAI reports. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $41.48 million during the quarter.

ChronoScale Corporation Common Stock Trading Down 8.8%

NASDAQ:CHRN opened at $14.88 on Thursday. ChronoScale Corporation Common Stock has a twelve month low of $3.50 and a twelve month high of $30.00. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $19.98 and a two-hundred day moving average price of $18.15. The company has a market cap of $2.17 billion, a P/E ratio of -2.77 and a beta of 0.98.

Get ChronoScale Corporation Common Stock alerts:

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc grew its holdings in ChronoScale Corporation Common Stock (NASDAQ:CHRN – Free Report) by 104.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,338 shares of the company’s stock after purchasing an additional 1,195 shares during the period. Roble Belko & Company Inc owned about 0.07% of ChronoScale Corporation Common Stock worth $25,000 at the end of the most recent quarter. Institutional investors own 6.42% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CHRN shares. Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Friday, October 9th. Northland Securities began coverage on shares of ChronoScale Corporation Common Stock in a research note on Friday, September 18th. They issued an “outperform” rating and a $32.00 target price for the company. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $19.00.

View Our Latest Stock Report on ChronoScale Corporation Common Stock

About ChronoScale Corporation Common Stock

(Get Free Report)

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

Read More

• Five stocks we like better than ChronoScale Corporation Common Stock
• Tesla Wants to Make Its Own Chips—What Could Go Wrong?
• IREN Limited’s AI Pivot Gains Traction—But Can Its Data Centers Deliver?
• PBF Energy’s Stunning Rally Faces a Critical Test
• Citi Stock Falls Despite Earnings Beat: What Investors Need to Know

Receive News & Ratings for ChronoScale Corporation Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChronoScale Corporation Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.